Table 3

Overall tophus complete response in patients over time during the randomized controlled trialsa
Variables Pegloticase Pegloticase Placebo
biweekly monthly
(n = 62) (n = 64) (n = 29)
Week 13
 Patients with evaluable tophi at visit, n 46 48 25
 CR, n (%) 10 (22) 4 (8) 0
P valueb 0.011 0.292
Week 25
 Patients with evaluable tophi at visit, n 40 39 24
 CR, n (%) 18 (45) 10 (26) 2 (8)
P valueb 0.002 0.110
Final visitc
 Patients with evaluable tophi, n 52 52 27
 CR, n (%) 21 (40) 11 (21) 2 (7)
P valueb 0.002 0.200

aCR, complete response. bPegloticase groups versus placebo for CR. cFinal visit includes data from the patient’s final visit, whenever it occurred, for all evaluable completers and noncompleters.

Baraf et al.

Baraf et al. Arthritis Research & Therapy 2013 15:R137   doi:10.1186/ar4318

Open Data